{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:23:25Z","timestamp":1791397405473,"version":"4.3.3"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118256","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:17:35Z","timestamp":1760501855000},"page":"118256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P1","title":["Discovery of a brain-penetrant fourth-generation EGFR inhibitor to overcome the human triple (L858R\/T790\u00a0M\/C797S) mutation"],"prefix":"10.1016","volume":"302","author":[{"given":"Lei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Sheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Chen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8913-6830","authenticated-orcid":false,"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118256_bib1","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1021\/acs.jmedchem.5b01073","article-title":"Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor","volume":"58","author":"Zeng","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118256_bib3","volume":"vol. 11","author":"Wang","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118256_bib4","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118256_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Nat. Cancer Center"},{"key":"10.1016\/j.ejmech.2025.118256_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118256_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118256_bib8","first-page":"115","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for Non\u2013small-cell lung cancer with mutated epidermal growth factor receptor: NE J009","volume":"38","author":"Hosomi","year":"2020","journal-title":"Study"},{"key":"10.1016\/j.ejmech.2025.118256_bib9","first-page":"2380","volume":"vol. 362","author":"Maemondo","year":"2010"},{"key":"10.1016\/j.ejmech.2025.118256_bib10","first-page":"1721","article-title":"Conformational insight on WT- and Mutated-EGFR receptor activation and inhibition by Epigallocatechin-3-Gallate: over a rational basis for the design of selective non-small-cell lung","volume":"21","author":"Minnelli","year":"2020","journal-title":"Anticancer Agents"},{"key":"10.1016\/j.ejmech.2025.118256_bib11","first-page":"573","article-title":"Covalent EGFR inhibitors: binding mechanisms, synthetic approaches","volume":"349","author":"Hossam","year":"2016","journal-title":"Clin. Profiles"},{"key":"10.1016\/j.ejmech.2025.118256_bib12","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118256_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3892\/or.2023.8675","article-title":"The advance of the third-generation EGFR-TKI in the treatment of non-small cell lung cancer(Review)","volume":"51","author":"Cheng","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2025.118256_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114643","article-title":"Fighting tertiary mutations in EGFR-driven lung-cancers: current advances and future perspectives in medicinal chemistry","volume":"190","author":"Scalvini","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118256_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jtho.2020.11.028","article-title":"Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors\u00a0For Advfnced <emaEGFR+<\/em> NSCLC","volume":"16","author":"Nagasaka","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.118256_bib16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41571-023-00808-4","article-title":"Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer","volume":"20","author":"Pan","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118256_bib17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1021\/acschembio.4c00028","article-title":"Chemical scaffolds for the clinical development of mutant-selective and reversible fourth-generation EGFR-TKIs in NSCLC","volume":"19","author":"Laudadio","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118256_bib18","first-page":"3290","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non & 2013","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"Small-Cell Lung Cancer"},{"key":"10.1016\/j.ejmech.2025.118256_bib19","first-page":"2702","volume":"vol. 36","author":"Wu","year":"2018"},{"key":"10.1016\/j.ejmech.2025.118256_bib20","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118256_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114900","article-title":"Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy","volume":"245","author":"Xu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib22","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/jps.24301","article-title":"Exploring <em>In silico<\/em> prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation","volume":"104","author":"Varadharajan","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.118256_bib23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118256_bib24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/acsmedchemlett.1c00555","article-title":"Optimization of brigatinib as new wild-type sparing inhibitors of EGFRT790M\/C797S mutants","volume":"13","author":"Li","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118256_bib25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2025.118256_bib26","first-page":"368ra172","volume":"vol. 8","author":"Yang","year":"2016"},{"key":"10.1016\/j.ejmech.2025.118256_bib27","doi-asserted-by":"crossref","first-page":"10030","DOI":"10.1021\/acs.jmedchem.6b00618","article-title":"Small molecule kinase inhibitors for the treatment of brain cancer","volume":"59","author":"Heffron","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib28","doi-asserted-by":"crossref","first-page":"13152","DOI":"10.1021\/acs.jmedchem.1c00910","article-title":"Strategies for structural modification of small molecules to improve blood\u2013brain barrier penetration: a recent perspective","volume":"64","author":"Xiong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijpharm.2019.02.012","article-title":"Chitosan and chitosan coating nanoparticles for the treatment of brain disease","volume":"560","author":"Yu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2025.118256_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood\u2013brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118256_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118256_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107313","article-title":"The new N2, N4-diphenylpyridine-2,4-diamine deuterated derivatives as EGFR inhibitors to overcome C797S-mediated resistance","volume":"146","author":"Liu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116711","article-title":"Novel EGFR inhibitors against resistant L858R\/T790M\/C797S mutant for intervention of non-small cell lung cancer","volume":"277","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib34","doi-asserted-by":"crossref","first-page":"14633","DOI":"10.1021\/acs.jmedchem.3c01165","article-title":"Discovery of novel fourth-generation EGFR inhibitors to overcome C797S-Mediated resistance","volume":"66","author":"Zhu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib35","doi-asserted-by":"crossref","first-page":"15477","DOI":"10.1021\/acs.jmedchem.3c01669","article-title":"Discovery of a hydroxylamine-based brain-penetrant EGFR inhibitor for metastatic non-small-cell lung cancer","volume":"66","author":"Hill","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115840","article-title":"Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19\/T790M\/C797S) mutation","volume":"261","author":"Jeon","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116590","article-title":"Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation","volume":"275","author":"Yao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib38","doi-asserted-by":"crossref","first-page":"20531","DOI":"10.1021\/acs.jmedchem.4c01975","article-title":"Design, synthesis, and biological evaluation of novel diaminopyrimidine macrocycles as fourth generation reversible EGFR inhibitors that overcome clinical resistance to osimertinib mediated by C797S mutation","volume":"67","author":"Hu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117323","article-title":"Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR\/ALK co-mutations","volume":"287","author":"He","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118256_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116858","article-title":"Design, synthesis, and biological evaluation of diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFRL858R\/T790M\/C797S inhibitors","volume":"279","author":"Dou","year":"2024","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:08:32Z","timestamp":1777529312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425010219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"alternative-id":["S0223523425010219"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118256","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a brain-penetrant fourth-generation EGFR inhibitor to overcome the human triple (L858R\/T790\u00a0M\/C797S) mutation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118256"}}